Novel agents for the control of secretory diarrhoea

Expert Opinion on Investigational Drugs

Volumn 13, Issue 7, 2004, Pages 777-785

  Farthing, Michael J G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

5 hydroxytryptamine; Acute diarrhoea; Antisecretory drugs; Enkephalins; Enteric nerves; Enterotoxins; Intestinal secretion; Substance P; Vasoactive intestinal polypeptide 1

Indexed keywords

ACETORPHAN; AMINOBENZOIC ACID DERIVATIVE; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; CHLORIDE CHANNEL; CHLORIDE CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CROFELEMER; DIPHENOXYLATE; ENKEPHALIN; ENKEPHALINASE INHIBITOR; GLIBENCLAMIDE; INFUSION FLUID; KETANSERIN; LOPERAMIDE; NEUROHORMONE; OCTREOTIDE; OPIATE AGONIST; ORAL REHYDRATION SOLUTION; RHODANINE; SEROTONIN; SEROTONIN ANTAGONIST; SIGMA OPIATE RECEPTOR; SOMATOSTATIN DERIVATIVE; STILBENEDISULFONIC ACID; SUBSTANCE P; SUBSTANCE P ANTAGONIST; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; ZALDARIDE MALEATE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE DIARRHEA; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FECES ANALYSIS; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IN VITRO STUDY; INTESTINE CELL; INTESTINE INNERVATION; MORBIDITY; MORTALITY; NONHUMAN; ORAL REHYDRATION THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; RESPIRATION DEPRESSION; REVIEW; TRAVELLER DIARRHEA;

ANIMALS; ANTIDIARRHEALS; DYSENTERY; HUMANS; INTESTINAL SECRETIONS;

EID: 3543146039     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.7.777     Document Type: Review

References (72)

1. FARTHING MJG: Acute diarrhea: pathophysiology. In: Diarrbeal Disease (Vol. 38). M Gracey. JA Walker-Smith (Eds), Vevey/Lippincott-Raven Publishers, Philadelphia (1997):55-71.
2. FARTHING MJG: Pathophysiology of infective diarrhoea. Eur. J. Gastroenterol. Hepatol. (1993) 5:796-807.
3. PARASHAR UD, BRESEE JS, GLASS RI: The global burden of diarrhoeal disease in children. Bull. World Health Organ. (2003) 81:236.
4. FARTHING MJG: Dehydration and rehydration in children. In: Hydration Throughout Life. MJ Arnaud (Ed.), John Libbey Eurotext, Paris (1998):159-173.
5. RAO MC: Molecular mechanisms of bacterial toxins. In: Enteric infection. MJG Farthing, GT Keusch (Eds), Chapman & Hall, London (1989):87-104.
6. FIELD M, FAO MC, CHANG EB: Intestinal electrolyte transport and diarrheal disease. N. Engl. J. Med. (1989) 321:879-883.
7. FIELD M, RAO MC, CHANG EB: Intestinal electrolyte transport and diarrheal disease. N. Engl. J. Med. (1989) 321:800-806.
8. RAO MC: Toxins which activate guanylate cyclase: heat-stable enterotoxins. In: Microbial Toxins and Diarrhoeal Disease. D Evered, J Whelan (Eds), Ciba Foundation Symposium 112, Pirman, London (1985):74-93.
9. ZHANG M, ZENG CO-Y, MORRIS AP, ESTES MK: A functional NS94 enterotoxin peptide secreted from rotavirus-infected cells. J. Virol. (2000) 74:11663-11670.
10. MOHAN KVK, DERMODY TS, ATREYA CD: Mutations selected in rotavirus enterotoxin NSP4 depend on the context of its expression. Virology (2000) 275:125-132.
11. MORRIS AP, ESTES MK: Microbes and microbial toxins: Paradigms for microbial-mucosal interactions VIII. Pathological consequences of rotavirus infection and its enterotoxin. Am. J. Physiol. (2001) 281:G303-G310.
12. FARTHING MJG: 5-Hydroxytryptamine and 5-hydroxytryptamine 3 receptor antagonists. Scand J. Gastroenterol. (1991) 188(Suppl.):92-100.
13. NILSSON O, CASSUTO J, LARSSON PA et al.: 5-Hydroxytryptamine and cholera secretion: a histochemical and physiological study in cats. Gut (1983) 24:542-548.
14. 2 is a mediator of 5-hydroxytryptamine induced water and electrolyte secretion in the human jejunum. Gut (1988) 29:1337-1341.
15. 2 and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of the rat in vivo. Gastroenterology (1989) 96:368-376.
16. BEARCROFT CP, PERRETT D, FARTHING MJG: 5-Hydroxytryptamine release into human jejunum by cholera toxin. Gut (1996) 39:528-531.
17. 3 receptor subtypes mediate cholera toxin-induced intestinal fluid secretion. Gastroenterology (1990) 99:83-89.
18. SJOQVIST A, CASSUTO J, JODAL M, LUNDGREN O: Actions of serotonin antagonists on cholera-induced intestinal fluid secretion. Acta Physiol. Scand. (1992) 145:229-237.
19. MOURAD FH, O'DONNELL LJ, DIAS JA et al.: Role of 5-hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and Escherichia coli enterotoxins. Gut (1995) 37:340-345.
20. BEUBLER E, SCHULIGOI R, CHOPRA AK, RIBARDO DA, PESKAR BA: Cholera toxin induces prostaglandin synthesis via post-transcriptional activation of cyclooxygenase-2 in the rat jejunum. J. Path. Exp. Therap. (2002) 297:940-945.
21. TURVILL JL, FARTHING MJG: Substance P (SP) antagonist inhibits cholera toxin but not E. coli enterotoxin-induced secretion. Gastroenterology (1999) 112-A414.
22. TURVILL JL, CONNOR P, FARTHING MJG: Neurokinin 1 and 2 receptors mediate cholera toxin secretion in rat jejunum. Gastroenterology (2000) 119:1037-1044.
23. POTHOULAKIS H, CATAGLIUOLO I, LAMONT T et al.: ICP-96,345, a substance P antagonist inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc. Natl. Acad. Sci. USA (1994) 91:947-951.
24. CASTAGLUIOLO I, LAMONT JT, LETOURNEAU R et al.: Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio enterotoxin in rat ileum. Gastroenterology (1994) 107:657-665.
25. FARTHING MICHAEL JG: Novel targets for the pharmacotherapy of diarrhoea - a view for the millennium. J. Gastroenterol. Hepatol. (2000) 15(Suppl.):C40-C47.
26. FARTHING MJG: Novel targets for the control of secretory diarrhoea. Gut (2002) 50(Suppl. 3):1-3.
27. FARTHING MJG, CASBURN-JONES A, BANKS MR: Getting control of intestinal secretion: thoughts for 2003. Dig. Liv. Dis. (2003) 35:378-385.
28. HUBEL KA: Intestinal nerves and ion transport: stimuli, reflexes and responses. Am. J. Physiol. (1985) 248:G261-G271.
29. JODAL M: Neuronal influence on intestinal transport. J. Intern. Med. (1990) 228:125-132.
30. COOKE HJ: Neurotransmitters in neuronal reflexes regulating intestinal secretion. Ann. AT Acad. Sci. (2000) 915:77-80.
31. POTHOULAKIS C: The role of neuroenteric hormones in intestinal infectious diseases. Curr. Opin. Gastroenterol. (2000) 16:536-540.
32. BANKS MR, CASBURN-JONES AC, FARTHING MJG: Cholera toxin (CT), Escherichia coli heat labile (LT) and heat stable toxin (STA) have an indirect effect on distal intestinal fluid transport in the rat small intestine. Gut (2002) (Suppl. II) A69.
33. CASBURN-JONES AC, BARNETT SC, FITZGERALD UF, FARTHING MJG: Cholera toxin (CT) Escherichia coli heat labile toxin (LT) and heat stable toxin (STA) have a direct effect on the neuronal-like PC12 cell line. Gut (2002) (Suppl. II) A26.
34. CASBURN-JONES AC, BARNETT SC, FARTHING MJG: Bacterial enterotoxins stimulate release of the neurotransmitter [3H] noradrenaline fiorn neuronally differentiated PC 12 cells. Gut (2004) (In press).
35. CASBURN-JONES AC, YOUNG C, HERZYK P, RIBOLDI-TUNNICLIFFE G, FARTHING MJG: Identification of differentially expressed genes following bacterial enterotoxin-induced neuronal growth and differentiation in PC12 cells. Gut (2004) (In press).
36. LUNDGREN O, PEREGRIN AT, PERSSON K, KORDASTI S, UHNOO I, SVENSSON L: Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea. Science (2000) 287:491-495.
37. JODAL M: Neuronal influence on intestinal transport. J. Intern. Med. (1990) 228:125-132.
38. CASSUTO J, FAHRENKRUG J, JODAL M, TUTTLE R, LUNDGREN O: Release of vasoactive intestinal polypeptide from the cat small intestine exposed to cholera toxin. Gut (1981) 22:958-963.
39. 3 receptor antagonist, granisetron, in the rat. Br. J. Pharmacol. (2000)130:1031-1036.
40. MOURAD FH, NASSAR C: Effect of vasoactive intestinal peptide (VIP) antagonism on rat jejunal fluid and electrolyte secretion induced by cholera and Escherichia coli enterotoxins. Gut (2000) 47:382-386.
41. BANKS MR, FARTHING MJG, ROBBERECHT P, BURLEIGH DE: Antisecretory actions of a novel vasoactive intestinal polypeptide receptor antagonist. Gastroenterology (2002) 122(4):A254.
42. TURVILL JL, KASAPIDIS P, FARTHING MJG: The sigma ligand, igmesine, inhibits cholera toxin and Escherichia coli enterotoxin induced jejunal secretion in the rat. Gut (1999) 45:564-569.
43. FARTHING MJG: The role of somatostatin analogues in the treatment of refractory diarrhoea. Digestion (1996) 57:107-112.
44. FRIED M: Octreotide in the treatment of refractory diarthea. Digestion (1999) 60:42-46.
45. ABBAS Z MOID I, KHAN AH et al.: Efficacy of octreotide in diarrhoea due to Vibrio cholerae: a randomized, controlled trial. Ann. Trop. Med. Parasitol. (1996) 90:507-513.
46. GARCIA COMPEAN D, RAMOS JIMENEZ J, GUZMAN DE LA GARZA F et al.: Octreotide therapy of large-volume refractory AIDS-asociated diarrhea: a randomized controlled trial. AIDS (1994) 8:1563-1567
47. SZILAGYI A, SHRIER I: Systematic review: the use of somatostatin or octreotide in refractory diarrhoea. Aliment. Pharmacol. Therap. (2001) 15:189-197.
48. TURVILL JL, FARTHING MJG: Enkephalins and enkephalinase inhibitors in intestinal fluid and electrolyte transport Eur. J. Gastro. Hepatol. (1997) 9:877-880.
49. FARTHING MJG: Enkephalinase inhibitiori: a rational approach to antisecretary therapy for acute diarrhoea. Aliment. Pharmacol. Ther. (1999) 13(Suppl. 6):1-2.
50. PRIMI MP, BEUNO L, BAUMER P, BERARD H, LECOMTE JE: Racecadotril demontrates intestinal anti-secretory activity in vivo. Aliment. Pharmacol. Ther. (1999) 13(Suppl. 6):3-7.
51. HAMZA H, KHALIFA HB, BAUMER P, BERARD H, LECOMTE JM: Racecadotril versus placebo in the treatment of acute diarrhoea in adults. Aliment. Pharmacol. Ther. (1999) 13(Suppl. 6):15-19.
52. LECOMTE JM: An overview of clinical studies with racecadotril in adults. Int. J. Antimicrob. Agents (2000) 14:81-87
53. PRADO D: A multinational comparison of racecadotril and loperamide in the treatment of watery diarrhoea in adults. Scand J. Gastroenterol. (2002) 37:656-661.
54. TURCK D, BERARD H, FRETAULT N, LECOMTE JM: Comparison of racecadotril and loperamide in children with acute diarrhoea. Aliment. Pharmacol. Ther. (1999) 13(Suppl. 6):27-32.
55. CEZARD JP, DUHAMEL JF, MEYER M et al.: Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterology (2001) 120:799-805
56. SALAZAR-LINDO E, SANTISTEBAN-PONCE J, CHEA-WOO E, GUTIERREZ M: Racecadotril in the treatment of acute watery diarrhea in children. N. Engl. J. Med. (2000) 343:463-467.
57. POWELL DW, FIELD M: Pharmacological approaches to treatment of secretory diarrhoea. In: Secretory Diarrhea. M Field, JS Fordtran, SG Schultz (Eds), American Physiological Society, Bethesda, MD, USA (1980):187-209.
58. AIKAWA N, KARASAWA A, OHMORI K: Effect of zaldaride maleate, an antidiarrheal compound, on intracellular cyclic nucleotide-mediated intestinal ion secretion in rats. Eur. J. Pharmacol. (2000) 394:233-236
59. SILBERSCHMIDT G, SCHICK MT, STEFFEN R et al.: Treatment of traveller's diarrhoea: zaldaride compared with loperamide and placebo. Eur. J. Gastroenterol. Hepatol. (1995) 7:871-875.
60. OKHUYSEN PC, DUPONT HL, ERICSSON CD et al.: Zaldaride maleate (a new calmodulin antagonist) versus loperamide in the treatment of traveler's diarrhoea: a randomised, placebo-controlled trial. Clin. Infect. Dis. (1995)21:341-344.
61. SCHULTZ BD, SINGH AK, DEVOR DC, BRIDGES RJ: Pharmacology of CFTR chloride channel activity. Physiol. Rev. (1999) 79(Suppl. 1):S109-S144
62. CAI Z, LANDSELL KA, SHEPPARD DN: Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator CT channels by nonsulphonylurea hypoglycaemic agents. Br. J. Pharmacol. (1999)128:108-118.
63. MA T, THIAGARAJAH JR, YANG H, et al.: Thiazolidinone CFTR inhibitor identified by high throughput screening blocks cholera toxin-induced intestinal fluid secretion. J. Clin. Invest. (2002) 110:1651-1658.
64. DICESARE D, DUPONT HL, MATHEWSON JJ et al.: A double-blind, randomized, placebo-controlled study of SP 303 (provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am. J. Gastroenterol. (2002)97:2585-2588.
65. THEODOROU V, CHOVET M, EUTAMENE H et al.: Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action. Gut (2002)51:522-528
66. ROZE C, BRULEY DES VARANNES S, SHI G, GENEVE J, GALMICHE JP: Inhibition of prostaglandin-induced intestinal secretion by igmesine in healthy volunteers. Gastroenterology (1998)115:591-596.
67. BEUBLER E, HORINA G: 5-HT3 receptor subtypes mediate cholera toxin-induced intestinal fluid secretion in the rat. Gastroenterology (1990) 99:83-89.
68. 3 receptor antagonist ICS 205-930. Arch. Pharmacol. (1989) 339-704-705.
69. EHERE AJ, HINTERLEITNER TA, PETRITSCH W, HOLZER PETSCHE U, BEUBLER E, KREJS GJ: Effect of 5-hydroxytryptamine antagonists on cholera toxin-induced secretion in the human jejunum. Eur. J. Clin. Invest. (1994) 24:664-668.
70. 3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion. Aliment. Pharm. Therap. (1997) 11:1109-1114.
71. TURVILL JL, FARTHING MJG: Effect of granisetron on cholera toxin-induced enteric secretion. Lancet (1997) 349:1293.
72. 4) antagonist inhibits cholera toxin (CT) but not E. coli heat labile toxin (LT)-induced secretion. Gastroenterology (1996) 110:A368.